Navigation Links
The International Myeloma Foundation Reports Positive Shift In,Treatment Paradigm For Patients

-Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID with Low Dose Steroids in Myeloma-

NORTH HOLLYWOOD, Calif., May 15, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said that for the second time in four weeks a multi-center myeloma trial using REVLIMID(R) has demonstrated positive findings and therefore has been halted early. As a result medical experts are backing the use of new, less toxic and more tolerable treatments for multiple myeloma, the second most common of the blood cancers in the United States.

    -- In April, the Eastern Cooperative Oncology Group (ECOG) stopped the use

       of high dose dexamethasone, a steroid commonly used when treating

       patients with REVLIMID, (lenalidomide) an oral medication from Celgene.

       Based on the findings, the data safety monitoring committee recommended

       all patients in the study be moved to a regimen of REVLIMID with low-

       dose dexamethasone, which demonstrated improved survival and was better

       tolerated.

    -- Now based on these findings and early analysis of its own data the

       Southwest Oncology Group (SWOG), the largest of the NIH sponsored

       multi-center cooperative group, has brought its trial of high dose

       dexamethasone versus Revlimid plus high dose dexamethasone to an early

       close and also recommended patients be transitioned to a REVLIMID/LDD

       regimen.

    -- Based on these findings, The International Myeloma Foundation's US

       MYELOMA FORUM, a committee of the nation's leading myeloma experts, is

       considering the first large, inter-group trial for newly-diagnosed

       patients using novel agents (either REVLIMID with low-dose

       dexamethasone  or REVLIMD plus other agents such as VELCADE(R) with

       low-dose dexameth
asone) without front-line transplant.

"This is an important series of steps for myeloma patients, as we now have regimens that are more tolerable and at the same time may be more effective," said Brian G.M. Durie, M.D., chairman and co-founder of the IMF and co-chair of the SWOG myeloma committee. "Based on this new clinical evidence, we believe that regimens that include REVLIMID with low dose steroid are an important option for patients with myeloma at all stages of the disease."

Susie Novis, president and co-founder of the IMF, added, "These findings are particularly exciting because the use of low dose dexamethasone was proposed by patients themselves, showing how much can be achieved when we empower patients and listen to what they have to say. In addition, closer cooperation between the two large cooperative groups, SWOG and ECOG, will provide important benefits to patients."

Myeloma, also called multiple myeloma, is a cancer of the bone marrow that affects production of red cells, white cells and stem cells. It affects an estimated 750,000 people worldwide, and in industrialized countries it is being diagnosed in growing numbers and in increasingly younger people.

ABOUT The International Myeloma Foundation

The International Myeloma Foundation is the oldest and largest myeloma organization, reaching more than 135,000 members in 113 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses on four key areas: research, education, support and advocacy. To date, the IMF has conducted more than 100 educational seminars worldwide, maintains a world-renowned hotline, and operates Bank on a Cure(R), a unique gene bank to advance myeloma research. The IMF can be reached at 818-487-7455. The global Website is http://www.myeloma.org with a companion Website in Spanish at http://www.myelomala.org.


    CONTACT:                                Media:

    International Myeloma Foundation        Stephen Gendel, BioCom Partners

    800 452-2873                            212 918-4650


CONTACT: The International Myeloma Foundation, +1-800-452-2873, or StephenGendel of BioCom Partners, +1-212-918-4650, for The International MyelomaFoundation

Web site: http://www.myeloma.org/http://www.myelomala.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... IRVINE, Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: ... quarter ended December 31, 2015. The Company also filed its ... fiscal year 2016 with the Securities and Exchange Commission today. ... December 31, 2015 --> --> ... 2015 increased $2.6 million, or 95%, to $5.4 million from ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 , ... new health technologies, announced today " 10 Year Global ... health tech over the past ten years.   ... a decade, Health 2.0 has served as the preeminent ... connected with thousands of technologies, companies, innovators, and patient-activists ...
(Date:2/11/2016)... , Feb. 11, 2016  AfterPill.com is reporting that ... alcohol abstinence for all women who are at risk ... U.S. each year and raises the risks of unprotected ... --> According to the Guttmacher Institute, there ... women of child-bearing age, who have sex without the ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 2016 , ... Hidden Cypress in Sun City is the place to be on March 3rd ... Frederick Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. ... special pricing on offers. In addition, prizes will be given away and light refreshments will ...
(Date:2/13/2016)... ... ... individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased their ... delved into this niche allowing those giving up their beloved pasta a chance to ... of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio that ...
(Date:2/13/2016)... Tennessee (PRWEB) , ... February 13, 2016 , ... ... the Infusion Nurses Society (INS) states that vein visualization technology should be used ... by healthcare facilities around the world, the INS Standards mandate the use of ...
(Date:2/13/2016)... ... , ... In the early or “honeymoon” stage of a relationship, couples strive ... their way to be romantic, and may exaggerate a strength or two in an ... profile. , A recent study from Queendom.com , however, suggests that new ...
(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
Breaking Medicine News(10 mins):